Summary of Key Points Core Viewpoint The company, Kailaiying Pharmaceutical Group (Tianjin) Co., Ltd., is undergoing changes in the use of raised funds, including new investment projects, adjustments in investment amounts, and delays in project timelines, to enhance operational efficiency and align with market opportunities. Group 1: Fundraising Overview - The company raised a total of RMB 2,277,875,164.30 from a non-public stock issuance, with a net amount of RMB 2,274,960,656.06 after deducting issuance costs [1][2] - The funds are stored in a dedicated account, regulated by a tripartite agreement among the company, the sponsor, and the bank [2] Group 2: Fund Usage Status - As of June 30, 2025, the company has allocated funds to various projects, including the expansion of its life sciences platform and the construction of a biopharmaceutical R&D base [3][4] - The total investment for the projects is RMB 228,070.62 million, with cumulative investments of RMB 163,909.18 million [4] Group 3: Changes in Fund Usage - The company has proposed to change the use of funds for the "Taixing Project" and redirect remaining funds to new projects, including a chemical macromolecule project and a high-end formulation project [5][6] - The investment amount for the Taixing Project will be reduced by RMB 400 million, with the remaining funds allocated to new projects [6][11] Group 4: New Investment Projects - A new project, the "Chemical Macromolecule Integration Project," will receive RMB 47,367.72 million from the remaining funds, with a total investment of RMB 50,800.00 million [11][12] - The project aims to enhance the company's capacity in the CDMO field and is expected to take 48 months to complete [12][14] Group 5: Financial Performance - The company's total assets as of December 31, 2024, were RMB 3,073,514,644.17, with total liabilities of RMB 2,080,120,300.01 and net assets of RMB 993,394,344.16 [13] - The company reported a revenue of RMB 1,597,172,881.12 and a net profit of RMB 52,163,151.56 for the same period [13] Group 6: Strategic Implications - The changes in fund usage are aligned with the company's long-term strategic planning and are expected to improve operational efficiency and competitiveness [19][20] - The company aims to leverage market trends and enhance its capabilities in innovative drug development, particularly in the chemical macromolecule sector [15][16]

Summary of Key Points Core Viewpoint - The company, Beijing Aerospace Changfeng Co., Ltd., is changing the use of raised funds from its 2022 private placement, terminating the "Energy Storage Power Verification Capability Construction Project" and permanently supplementing remaining funds into working capital due to changes in market conditions and strategic focus [2][4][6]. Group 1: Fundraising Overview - The company raised a total of RMB 325.26 million by issuing 27,752,474 shares at a price of RMB 11.72 per share [2]. - The funds were intended for projects including the enhancement of high-power density module power supply production and AI-based detection equipment development, with a total investment of RMB 393.04 million [2][3]. Group 2: Change of Fund Usage - The "Energy Storage Power Verification Capability Construction Project" was planned to invest RMB 63.52 million, with RMB 52.50 million from the raised funds, but has not yet utilized the funds [3]. - The decision to terminate this project is based on significant changes in the market environment and competitive landscape, which have compressed profit margins in the large energy storage industry [3][4]. Group 3: Remaining Fund Allocation - After terminating the project, the company plans to permanently allocate the remaining funds of RMB 53.88 million (including interest) to working capital, enhancing operational efficiency and strategic development [4][5]. - The company will close the corresponding special fund account and terminate the related fund supervision agreement after the transfer [4]. Group 4: Approval Process - The board of directors approved the change in fund usage unanimously on July 1, 2025, and the matter will be submitted to the shareholders' meeting for further approval [5][6]. - Independent directors and the supervisory board have expressed support for the decision, emphasizing that it aligns with the company's operational needs and does not harm shareholder interests [5][6].

Core Viewpoint - The company has decided to change the use of raised funds and permanently supplement the remaining funds into working capital, which is deemed a prudent decision based on market conditions and the company's strategic development needs [1][2]. Group 1 - The 15th meeting of the 10th Supervisory Board was held on July 1, 2025, with all three supervisors present, complying with relevant laws and regulations [1]. - The Supervisory Board unanimously approved the proposal to change the use of raised funds and permanently supplement the remaining funds into working capital, with a voting result of 3 votes in favor, 0 abstentions, and 0 votes against [2][3]. - The decision is based on a careful assessment of market environment changes, project implementation status, and the company's transformation and strategic development needs, aiming to improve the efficiency of fund usage without harming the interests of the company and its shareholders [2]. Group 2 - The proposal will be submitted to the company's shareholders' meeting for further approval [2].

Group 1 - The company has approved the investment in the Suez Phosphate Chemical Project in Egypt, which will produce 800,000 tons of sulfuric acid, 300,000 tons of industrial wet-process crude phosphoric acid, and 150,000 tons of other products annually [1] - The company plans to change the use of raised funds from a lithium iron phosphate precursor material project to the Suez Phosphate Chemical Project, pending approval from the upcoming shareholders' meeting [2] - The company has received necessary approvals from the Yunnan Provincial Development and Reform Commission and the Yunnan Provincial Department of Commerce for the overseas investment project [2]

Group 1 - The company announced a change in the use of part of the raised funds and a delay in investment projects, specifically reducing the investment amount for the "Konjac Deep Processing Intelligent Manufacturing Production Line Expansion and Renovation Project" from 101.05 million yuan to 91.36 million yuan, reallocating 26 million yuan for the construction of the Hydrophilic Colloid Industrial Park Renovation and Digital Transformation Project (Phase I) [2] - The "Konjac Deep Processing Intelligent Manufacturing Production Line Expansion and Renovation Project" was initially planned in 2022 based on market conditions and company circumstances, and the company has adhered to regulations regarding the use of raised funds while ensuring the project's smooth implementation [2] - As of May 31, 2025, the basic construction of the project, including civil works and equipment, has been completed [2] Group 2 - The company plans to extend the "Konjac Deep Processing Intelligent Manufacturing Production Line Expansion and Renovation Project" deadline to December 2025, utilizing working capital during the extension period to purchase raw materials needed for production [3] - The total planned investment for the "Hydrophilic Colloid Industrial Park Renovation and Digital Transformation Project (Phase I)" is 56.04 million yuan, with 26 million yuan sourced from the original raised funds, while the remaining amount will be financed through the company's own or self-raised funds [3] - The completion of the project is expected to enhance the company's production capacity for hydrophilic colloids, meet market demand, and improve the company's market competitiveness and profitability, thereby expanding future development opportunities [3]

Group 1 - The company, O-Film, announced on June 27 that it will hold the eighth (temporary) meeting of the sixth board of directors on June 27, 2025, to review the proposal for changing part of the fundraising purpose and adding new investment projects [2] - The company agreed to change the use of part of the raised funds, reallocating 200 million yuan from the "Hefei Jingchao Optical Technology Co., Ltd. Optical Lens and Lens Production Line Project" and 353.7568 million yuan from the "High-Pixel Optical Lens Construction Project" to the new project "High-Precision Optical Lens Production Line Upgrade and Expansion Project" [2] - The total amount of funds involved in this change is 553.7568 million yuan, which accounts for 15.76% of the net amount raised from the company's non-public stock issuance [2] Group 2 - The company’s revenue composition for the year 2024 is entirely from the manufacturing of optical and optoelectronic components, accounting for 100.0% [3]

Group 1 - The fifth meeting of the supervisory board of Ningbo Top Group Co., Ltd. was held on June 17, 2025, with all three supervisors present, complying with relevant laws and regulations [1][2] - The supervisory board approved the proposal to change the use of part of the raised funds, stating that the adjustment aligns with the company's strategic planning and actual development, enhancing the efficiency of fund utilization [1][2] - The supervisory board also approved the proposal for the postponement of some fundraising projects, emphasizing that this decision is also aimed at rational fund utilization and does not harm the interests of the company and its shareholders [2]

宁波拓普集团股份有限公司 会议材料 证券代码：601689 目 录 一、2025 年第二次临时股东大会议程 网络投票时间：自2025年7月3日至2025年7月3日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即9:15-9:25，9:30-11:30，13:00-15:00。 通过互联网投票平台的投票时间为股东大会召开当日的9:15-15:00。 现场会议时间：2025年7月3日14：00 现场签到时间：2025年7月3日13：20－13：50 现场会议地点：宁波市北仑区育王山路268号公司总部 C-105 会议室 会议主持人：董事长邬建树 （一）签到 料（授权委托书、营业执照复印件、身份证复印件等）并领取表决票。 宁波拓普集团股份有限公司董事会 二、2025 年第二次临时股东大会会议须知 人录音、拍照及录像。对于干扰会议正常秩序、寻衅滋事和侵犯股东合法权益 的行为，工作人员有权予以制止，并及时报告有关部门查处。 能选择现场投票或网络投票中的一种表决方式，不能重复投票。股东可以在网 络投票时间内通过上海证券交易所的交易系统行使表决权。同一股份通过现场 方式和 ...

东兴证券股份有限公司 关于华夏航空股份有限公司变更募集资金用途 及部分募集资金投资项目实施主体的核查意见 东兴证券股份有限公司（以下简称"东兴证券"、"保荐机构"），作为华夏航空 股份有限公司（以下简称"华夏航空"、"公司"）2022年度非公开发行股票的持续督 导机构，根据《证券发行上市保荐业务管理办法》、《上市公司募集资金监管规 则》、《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作 》等有关规定，对华夏航空变更募集资金用途及部分募集资金投资项目实施主体 的事项进行了审慎核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准华夏航空股份有限公司非公开发行股 票的批复》（证监许可【2022】1662号）的核准，华夏航空股份有限公司向特定 对象非公开发行人民币普通股不超过304,070,293股，每股面值为人民币1.00元，募 集资金总额不超过243,500万元。公司实际非公开发行A股股票264,673,906股，每股 发行价格为人民币9.20元，募集资金总额为人民币2,434,999,935.20元，扣除发行费 用人民币25,397,899.32元（不含税）后，募集资 ...

证券代码：002928 证券简称：华夏航空 公告编号：2025-031 公司召开本次股东大会已经公司第三届董事会第十九次会议审议通过。 公司法》等有关法律、行政法规、部门规章、规范性文件、深圳证券交易所业务 规则和《华夏航空股份有限公司章程》的规定。 （1）现场会议召开时间：2025 年 07 月 03 日（星期四）14:30 （2）网络投票时间： 深圳证券交易所交易系统投票时间：2025 年 07 月 03 日 09:15～09:25， 深圳证券交易所互联网投票系统投票时间：2025 年 07 月 03 日 09:15～15:00。 召开。 华夏航空股份有限公司 关于召开 2025 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 华夏航空股份有限公司（以下简称"公司"）将于 2025 年 07 月 03 日召开 络投票相结合的方式召开，现将本次股东大会有关事项通知如下： 一、召开会议的基本情况 （1）截至股权登记日 2025 年 06 月 30 日（星期一）下午收市时，在中国证 券登记结算有限责任公司深圳分公司登记在册的公司全体普 ...